The cardiovascular drug market has seen big developments in recent years, as warfarin and old-line statins have given way to next-generation blood thinners and novel, high-priced cholesterol fighters.

As a new age of price negotiations dawns in the U.S., drug cost watchdogs at the Institute for Clinical and Economic Review (ICER) are laying out their stance on two popular blood thinners. Monday, ...